The innovative evolution of cancer gene and cellular therapies

被引：0

作者：

P Lam

G Khan

R Stripecke

K M Hui

N Kasahara

K-W Peng

B-A Guinn

机构：

[1] National Cancer Centre,Division of Cellular and Molecular Research

[2] University of Bedfordshire,Department of Life Sciences

[3] Lymphatic Cell Therapy Program,Department of Biochemistry

[4] Excellence Cluster for Regenerative Biology (REBIRTH),Department of Medicine

[5] Hannover Medical School,Department of Molecular Medicine

[6] Yong Loo Lin School of Medicine,Department of Haematological Medicine

[7] National University of Singapore,undefined

[8] Program in Cancer and Stem Cell Biology,undefined

[9] Duke-NUS Graduate Medicinal School,undefined

[10] David Geffen School of Medicine,undefined

[11] University of California Los Angeles,undefined

[12] Mayo Clinic,undefined

[13] Cancer Sciences Unit,undefined

[14] Somers Cancer Sciences Building,undefined

[15] Southampton University Hospitals,undefined

[16] University of Southampton,undefined

[17] King’s College London School of Medicine,undefined

来源：

Cancer Gene Therapy | 2013年 / 20卷

关键词：

stem cells; immunotherapy; cancer research;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We provide an overview of the latest developments in cancer gene therapy—from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the ‘Valley of Death’. The treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen’s acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field.

引用

页码：141 / 149

页数：8

共 50 条

[31] Surge in Cellular and Gene Therapies Challenges FDA
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2020, 33 (09) : 8 - 9
[32] Delivery of Gene and Cellular Therapies for Heart Disease
Justin A. Mariani
David M. Kaye
Journal of Cardiovascular Translational Research, 2010, 3 : 417 - 426
[33] Emerging cellular and gene therapies for congenital anemias
Ludwig, Leif S.
Khajuria, Rajiv K.
Sankaran, Vijay G.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2016, 172 (04) : 332 - 348
[34] The rapid evolution of cellular therapies for the treatment of hip osteonecrosis
Homma, Yasuhiro
Sand, Theodore
Hernigou, Philippe
CURRENT ORTHOPAEDIC PRACTICE, 2014, 25 (02): : 164 - 168
[35] Evolution to a New Clinical Research Environment for Cellular Therapies
Elorza, Izaskun
BIOPHARM INTERNATIONAL, 2022, 35 (07) : 16 - +
[36] Possibilities of gene therapies for cancer
Lashford, LS
ANNALS OF MEDICINE, 1997, 29 (01) : 1 - 4
[37] Equal access to innovative therapies and precision cancer care
Agnès Buzyn
Jean-Yves Blay
Natalie Hoog-Labouret
Marta Jimenez
Frédérique Nowak
Marie-Cécile Le Deley
David Pérol
Christian Cailliot
Jacques Raynaud
Gilles Vassal
Nature Reviews Clinical Oncology, 2016, 13 : 385 - 393
[38] Equal access to innovative therapies and precision cancer care
Buzyn, Agnes
Blay, Jean-Yves
Hoog-Labouret, Natalie
Jimenez, Marta
Nowak, Frederique
Le Deley, Marie-Cecile
Perol, David
Cailliot, Christian
Raynaud, Jacques
Vassal, Gilles
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (06) : 385 - 393
[39] DRUG REPURPOSING AS A SOURCE OF INNOVATIVE THERAPIES IN CERVICAL CANCER
Capistrano, R.
Paul, S.
Boere, I. A.
Pantziarka, P.
Chopra, S.
Nout, R.
Bouche, G.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A9 - A10
[40] Pancreas cancer . From molecular biology to innovative therapies?
Eckel, F.
Schneider, G.
Schmid, R.
GASTROENTEROLOGE, 2006, 1 (01): : 27 - 33

← 1 2 3 4 5 →